Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 51 out of 100. How common it is

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

The global burden of AD and other dementias has significantly increased, with the highest incidence, prevalence, and DALYs observed in East Asia. A notable increase in prevalence was observed in females over 65 years compared to males. Joinpoint regression analysis revealed substantial changes in trends in 1995, 2005, 2011, and 2019, with a noticeable acceleration post-2011, especially after 2019. Age was a significant risk factor, with a sharp increase in risk after 60 years of age. Epidemiological changes had a minor impact globally but varied by region and gender. Bayesian age-period-cohort modeling predicts sustained growth through 2040, with age-standardized incidence and prevalence rates projected to reach 144.85 and 821.80 per 100,000 respectively, driven predominantly by aging populations in high SDI regions and demographic expansion in low SDI regions. The global burden of AD and other dementias is escalating, with a pronounced increase expected by 2040. This study highlights the need for targeted interventions, particularly in regions with higher burdens and among older populations. The findings underscore the importance of considering SDI, age, and gender when planning public health strategies to address the growing challenge of AD and other dementias.

What this study adds

Evidence grade: Moderate

The global burden of Alzheimer's disease and other dementias has increased significantly, with the highest incidence, prevalence, and DALYs in East Asia, and is projected to keep growing through 2040. The authors emphasize the need for targeted interventions, particularly in higher-burden regions and among older populations.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Hao, M., & Chen, J. (2025). Trend analysis and future predictions of global burden of alzheimer’s disease and other dementias: a study based on the global burden of disease database from 1990 to 2021. BMC Medicine. https://doi.org/10.1186/s12916-025-04169-w

Vancouver

Hao M, Chen J. Trend analysis and future predictions of global burden of alzheimer’s disease and other dementias: a study based on the global burden of disease database from 1990 to 2021. BMC Medicine. 2025. doi:10.1186/s12916-025-04169-w. PMID: 40597083.

BibTeX

@article{hao2025-40597083,
  author  = {Hao, Miao and Chen, Jiajun},
  title   = {{Trend analysis and future predictions of global burden of alzheimer’s disease and other dementias: a study based on the global burden of disease database from 1990 to 2021}},
  journal = {BMC Medicine},
  year    = {2025},
  doi     = {10.1186/s12916-025-04169-w},
  pmid    = {40597083},
  url     = {https://doi.org/10.1186/s12916-025-04169-w}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

The global burden of Alzheimer's disease and other dementias has increased significantly, with the highest incidence, prevalence, and DALYs in East Asia, and is projected to keep growing through 2040. The authors emphasize the need for targeted interventions, particularly in higher-burden regions and among older populations.

Study details

How this study scored 51/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 0 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 4 of 7; Citations per year 4 of 5; Impact for its field and year 6 of 6; Cited by studies here 1 of 6; Still being cited 3 of 4; Senior author's track record 2 of 4; Institution's track record 0 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 51 of 100.51 of 100 points earned49 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (BMC Medicine)
Journal's citation record 3 / 4 BMC Medicine: journal h-index 259 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 4 / 7 Cited 80 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 26.7 citations a year over 3 year(s) since 2025
Impact for its field and year 6 / 6 Cited 50.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 3 / 4 Cited 80 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Jiajun Chen: h-index 28 (OpenAlex, whole career)
Institution's track record 0 / 3 Jilin University: institution h-index 649 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40597083)
Free to read 2 / 2 Free to read
Total 51 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in How common it is from nearby years

Also in How common it is

80 studies in the library are filed under How common it is with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The How common it is hub.

Similar studies

More on How common it is

See all studies in How common it is →